52-week open-label extension (156 enrolled, 152 treated, 34 completed) of xanomeline/trospium in adults with schizophrenia: 53.3% had a treatment-emergent adverse event, mostly mild-moderate gastrointestinal; no new safety issues and PANSS improvement persisted.
RCTn = 156
Kaul et al. Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial